<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>02799nam a2200289   4500</leader>
  <controlfield tag="001">ESSALUD</controlfield>
  <controlfield tag="005">20260804122304.0</controlfield>
  <controlfield tag="007">ta</controlfield>
  <controlfield tag="008">      t        pe ||||| |||| 00| 0 spa d</controlfield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">BMG</subfield>
  </datafield>
  <datafield tag="041" ind1=" " ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Daemen, Joost </subfield>
    <subfield code="e">Autor</subfield>
    <subfield code="9">53647</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Angiography-based physiology to guide coronary revascularization</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">p&#xE1;ginas: 20-31</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Background: Current society guidelines recommend physiological assessment of intermediate coronary lesions to guide revascularization. Data regarding revascularization guided by vessel fractional flow reserve (vFFR), derived from three-dimensional quantitative coronary angiography without the need for a pressure wire or hyperemic agent, as compared with pressure-wire&#x2013;based fractional flow reserve (FFR), are lacking.
Methods: We conducted an international, open-label, randomized, noninferiority trial at 37 sites in Europe. Patients with intermediate coronary-artery lesions (diameter stenosis of 30 to 80%) who presented with chronic or acute coronary syndromes were randomly assigned in a 1:1 ratio to undergo either vFFR-guided or FFR-guided revascularization of the intermediate coronary-artery lesions. The primary end point was a composite of death from any cause, any myocardial infarction, or any revascularization at 1 year. The noninferiority margin was 3.0 percentage points.
Results: The primary end point was assessed in 1116 patients in the vFFR group and 1095 in the FFR group. The mean age of the patients was 67 years, 24.3% were women, 18.7% presented with an acute coronary syndrome, and 26.6% had diabetes mellitus. At 1 year, a primary end-point event had occurred in 80 patients (Kaplan&#x2013;Meier estimate, 7.5%) in the vFFR group and in 79 patients (Kaplan&#x2013;Meier estimate, 7.5%) in the FFR group (risk difference, &#x2212;0.02 percentage points; 95% confidence interval, &#x2212;2.25 to 2.21; P=0.004 for noninferiority). The incidence of serious adverse events appeared to be similar in the two groups.
Conclusions: Among patients with intermediate coronary lesions, vFFR-guided revascularization was noninferior to FFR-guided revascularization with respect to a composite of death, myocardial infarction, or revascularization at 1 year. 
</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">CARDIOLOG&#xCD;A GENERAL</subfield>
    <subfield code="9">53638</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">ENFERMEDAD CORONARIA</subfield>
    <subfield code="9">14895</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">INFARTO DE MIOCARDIO</subfield>
    <subfield code="9">13202</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Van der Eijk, Jari A. </subfield>
    <subfield code="9">53648</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Barbierato, Marco </subfield>
    <subfield code="9">53649</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Byrne, Robert A. </subfield>
    <subfield code="9">38050</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Canova, Paolo</subfield>
    <subfield code="9">53650</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">De Maria, Giovanni L. </subfield>
    <subfield code="9">53651</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Van Belle, Eric </subfield>
    <subfield code="9">53652</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="0">22717</subfield>
    <subfield code="9">22634</subfield>
    <subfield code="d">Massachusetts NEJM Group</subfield>
    <subfield code="o">NEJM001</subfield>
    <subfield code="t">The New England Journal of Medicine </subfield>
    <subfield code="w">ESSALUD</subfield>
    <subfield code="x">0028-4793</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="c">ARTICULOS</subfield>
    <subfield code="e">2026-07-31</subfield>
    <subfield code="z">sqb</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">22722</subfield>
    <subfield code="d">22722</subfield>
  </datafield>
</record>
